Author:
Möhler Markus,Al-Batran Salah-Eddin,Götze Thorsten Oliver
Reference40 articles.
1. Al-Batran S-E, Goetze TO, Mueller DW et al.: The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17(1) (2017) 893. doi:10.1186/s12885-017-3918-9.
2. Al-Batran S-E, Homann N, Pauligk C et al.: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet 393 (2019) 1948–1957.
3. Bang Y-J, Van Cutsem E, Feyereislova A et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010) 687–697.
4. Bass AJ, Thorsson V, Shmulevich I et al.: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014) 202–209.
5. Beyer K, Baukloh AK, Kamphues C et al.: Laparoscopic versus open gastrectomy for locally advanced gastric cancer: A systematic review and meta-analysis of randomized controlled studies. World J Surg Oncol 17 (2019) 1–19.